Konjac glucomannan exerts regulatory effects on macrophages and its applications in biomedical engineering

Carbohydrate Polymers, Год журнала: 2024, Номер 345, С. 122571 - 122571

Опубликована: Авг. 5, 2024

Язык: Английский

---

Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS)

International Journal of Pharmaceutics, Год журнала: 2024, Номер 657, С. 124182 - 124182

Опубликована: Апрель 30, 2024

Язык: Английский

---

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review

Pharmaceutics, Год журнала: 2024, Номер 16(5), С. 680 - 680

Опубликована: Май 17, 2024

Lung diseases have received great attention in the past years because they contribute approximately one-third of total global mortality. Pulmonary drug delivery is regarded as one most appealing routes to treat lung diseases. It addresses numerous drawbacks linked traditional dosage forms. presents notable features, such as, for example, a non-invasive route, localized delivery, low enzymatic activity, degradation, higher patient compliance, and avoiding first-pass metabolism. Therefore, pulmonary route commonly explored delivering drugs both locally systemically. Inhalable nanocarrier powders, especially, lipid nanoparticle formulations, including solid-lipid nanostructured-lipid nanocarriers, are attracting considerable interest addressing respiratory thanks their significant advantages, deep deposition, biocompatibility, biodegradability, mucoadhesion, controlled released. Spray drying scalable, fast, commercially viable technique produce nanolipid powders. This review highlights ideal criteria inhalable spray-dried SLN NLC powders administration route. Additionally, promising inhalation devices, known dry powder inhalers (DPIs) powder-based medications, applications treating chronic conditions, considered.

Язык: Английский

---

The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy

Pharmaceutics, Год журнала: 2024, Номер 16(8), С. 969 - 969

Опубликована: Июль 23, 2024

Lung cancer is the leading cause of cancer-related mortality worldwide, largely due to limited efficacy anticancer drugs, which primarily attributed insufficient doses reaching lungs. Additionally, patients undergoing treatment experience severe systemic adverse effects distribution drugs non-targeted sites. In light these challenges, there has been a growing interest in pulmonary administration for lung cancer. This route allows be delivered directly lungs, resulting high local concentrations that can enhance antitumor while mitigating toxic effects. However, poses challenge overcoming mechanical, chemical, and immunological defenses respiratory tract prevent inhaled drug from properly penetrating To overcome drawbacks, use nanoparticles inhaler formulations may promising strategy. Nanoparticles assist minimizing clearance, increasing penetration into epithelium, enhancing cellular uptake. They also facilitate increased stability, promote controlled release, delivery target sites, such as tumor environment. Among them, chitosan-based demonstrate advantages over other polymeric nanocarriers their unique biological properties, including activity mucoadhesive capacity. These properties have potential when administered via route. view above, this paper provides an overview research conducted on drug-loaded incorporated devices Furthermore, article addresses emerging technologies, siRNA (small interfering RNA), context therapy. Particularly, recent studies employing are described.

Язык: Английский

---

Current advances in the therapeutic potential of nanomedicines for pulmonary disorders

Emergent Materials, Год журнала: 2024, Номер unknown

Опубликована: Апрель 24, 2024

Язык: Английский

---

Understanding the role of swirling flow in dry powder inhalers implications for design considerations and pulmonary delivery

Journal of Controlled Release, Год журнала: 2024, Номер 373, С. 410 - 425

Опубликована: Июль 24, 2024

Dry powder inhalers (DPIs) are widely employed to treat respiratory diseases, offering numerous advantages such as high dose capacity and stable formulations. However, they usually face challenges in achieving sufficient pulmonary drug delivery minimizing excessive oropharyngeal deposition. This review provides a new viewpoint address these by focusing on the role of swirling flow, crucial yet under-researched aspect that induces strong turbulence. In review, we comprehensively discuss both key classic designs (tangential inlet, chamber, grid mesh, mouthpiece) innovative inhalers, exploring how induced flow initiates dispersion promotes efficiency. Valuable design considerations effectively coordinate with formulations patients also provided. It is highlighted delicate manipulation essential maximize benefits. By emphasizing its potential application, this offers promising insights for advancing DPI technology optimizing therapeutic outcomes inhaled therapy.

Язык: Английский

---

Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations

AAPS PharmSciTech, Год журнала: 2024, Номер 25(6)

Опубликована: Авг. 2, 2024

Язык: Английский

---

Revolutionizing Lung Cancer Treatment with Smart Pulmonary Drug Delivery Nanosystems

Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер 101, С. 106158 - 106158

Опубликована: Сен. 6, 2024

Язык: Английский

---

Enhancing Lung Recovery: Inhaled Poly(lactic-co-glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

ACS Nano, Год журнала: 2025, Номер unknown

Опубликована: Фев. 18, 2025

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing failure condition, results in high mortality rate, especially severe cases. Numerous trials have investigated various pharmacotherapy approaches, but their effectiveness remains uncertain. Here, we present an inhaled nanoformulation of fingolimod (FTY720)-nobiletin (NOB)- poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) with good biocompatibility and sustained-release pharmacological effect. The formulation decreases the toxicity FTY720 increases bioavailability NOB since use PLGA to encapsulate at same time. In vitro, comparison treatment pure drug, demonstrated that FTY720-NOB-PLGA NPs can reduce interleukin-6 (IL-6) reactive oxygen species (ROS) release by macrophages after lipopolysaccharide (LPS) stimulation more efficiently. vivo, used inhalation tower system allowed exposure unanesthetized mice aerosolized under controlled conditions. We attenuate LPS suppressing cytokine release, such as IL-6 tumor necrosis factor-α (TNF-α). trigger pathway ALI, including nuclear factor κ-light-chain-enhancer activated B cells (NF-κB) p38 mitogen-activated protein kinase, was also efficiently inhibited. Furthermore, provided safety profile, without detrimental effects on biochemical markers function. feasibility administering noninvasively continuous monitoring developed show excellent promise for acute therapy future.

Язык: Английский

---

Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?

Materials Today Bio, Год журнала: 2025, Номер 31, С. 101616 - 101616

Опубликована: Фев. 26, 2025

Язык: Английский

---